Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma

After the completion of screening, the subjects received cryoablation treatment

Three days after cryoablation, the patients receive intravenous infusion of Tislelizumab (200mg, with 100mL of normal saline) and Bevacizumab (dose 15mg/kg, with 100mL of normal saline) .The patients will receive Tislelizumab (200 mg, with 100 mL of normal saline) and Bevacizumab (15 mg/kg, with 100 mL of normal saline) once every 3 weeks until disease progression.